Drugs / 9-HPV vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06756269 Comparator | Jan → Oct 2025 overdue | human papilloma virus infection, human papillomavirus-related squamous cell carcinoma, intraepithelial neoplasia, viral sexually transmitted disease | Shanghai Bovax Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9-HPV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756269 ↗ |
| Modality | Vaccine | “9-HPV vaccine” NCT06756269 ↗ |
| Route | Intramuscular | “9-HPV vaccine intramuscular into the upper arm deltoid muscle” NCT06756269 ↗ |